https://www.solvonis.com/ https://www.solvonis.com/therapeutic-focus https://www.solvonis.com/pipeline https://www.solvonis.com/about https://www.solvonis.com/svn-001 https://www.solvonis.com/svn-002 https://www.solvonis.com/svn-015 https://www.solvonis.com/svn-114 https://www.solvonis.com/investors https://www.solvonis.com/investors/announcements https://www.solvonis.com/investors/presentations https://www.solvonis.com/investors/resources https://www.solvonis.com/investors/governance https://www.solvonis.com/investors/share-information https://www.solvonis.com/investors/advisers https://www.solvonis.com/news https://www.solvonis.com/contact https://www.solvonis.com/privacy https://www.solvonis.com/cookies https://www.solvonis.com/news/solvonis-and-icad-sign-mou-to-advance-planned-european-expansion-of-svn-001-phase-3 https://www.solvonis.com/news/svn-001-ahead-of-established-and-emerging-aud-treatments https://www.solvonis.com/news/vital-patent-milestone-achieved-svn-114 https://www.solvonis.com/news/solvonis-raises-1-3-million https://www.solvonis.com/news/svn-015-advances-in-nida-funded-studies https://www.solvonis.com/news/water-tower-research-initiates-coverage https://www.solvonis.com/news/solvonis-announces-positive-svn-002-bridging-data https://www.solvonis.com/news/solvonis-announces-result-of-annual-general-meeting https://www.solvonis.com/news/cso-speaks-at-us-national-research-meeting https://www.solvonis.com/news/financial-year-2025-results-svn-001-strategy-refinement https://www.solvonis.com/news/solvonis-appoints-water-tower-research https://www.solvonis.com/news/trumps-eo-positive-signal-for-rapid-acting-cns-therapies-in-the-us https://www.solvonis.com/news/second-us-patent-from-ptsd-programme https://www.solvonis.com/news/solvonis-granted-us-patent-from-ptsd-discovery-programme https://www.solvonis.com/news/svn-114-selected-as-the-lead-candidate-for-ptsd-discovery-programme https://www.solvonis.com/news/expansion-of-svn-015-into-depression-following-positive-preclinical-data https://www.solvonis.com/news/us-patent-allowance-received-for-ptsd-discovery-programme https://www.solvonis.com/news/research-and-development-update-q4-2025 https://www.solvonis.com/news/svn-015-accepted-into-us-nida-funded-addiction-treatment-discovery-program-for-methamphetamine-and-cocaine-addiction https://www.solvonis.com/news/solvonis-appoints-global-biopharma-leader-paul-carter-as-non-executive-director-to-support-next-phase-of-strategic-growth https://www.solvonis.com/news/raises-1-25-million-to-accelerate-programmes-in-high-burden-cns-disorders https://www.solvonis.com/news/svn-sdn-14-ptsd-positive-pre-clinical-results https://www.solvonis.com/news/1-0-million-subscription-by-major-shareholders-to-accelerate-ai-drug-discovery-programme https://www.solvonis.com/news/initiation-of-research-coverage-by-singer-capital-markets https://www.solvonis.com/news/allowance-of-u-s-patent-covering-ai-supported-cns-discovery-programme-compounds https://www.solvonis.com/news/initiation-of-artificial-intelligence-supported-cns-drug-discovery-programme https://www.solvonis.com/news/completion-of-the-acquisition-of-awakn-life-sciences-corp https://www.solvonis.com/news/statement-on-the-appointment-dr-renata-crome-non-executive-director